A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Overview

The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) extended release suspensions in different conditions in healthy adult participants.

Full Title of Study: “A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivirine Extended-Release Suspension”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: August 23, 2023

Interventions

  • Drug: RPV LA
    • RPV LA will be administered at different formulations.

Arms, Groups and Cohorts

  • Experimental: Panel A: Rilpivirine (RPV) Long-acting (LA)
    • Patients will receive one dose of RPV LA (formulation 1) under different conditions (Treatment A and B) on Day 1.
  • Experimental: Panel B: RPV LA
    • Patients will receive one dose of RPV LA (formulation 2) under different conditions (Treatment C and D) on Day 1.
  • Experimental: Panel C: RPV LA
    • Patients will receive one dose of RPV LA (formulation 1) under different conditions (Treatment E and F) on Day 1, based on interim data of Panel A and/or B.
  • Experimental: Panel D: RPV LA
    • Patients will receive one dose of RPV LA (formulation 2) under different conditions (Treatment G and H) on Day 1, based on interim data of Panel A and/or B.

Clinical Trial Outcome Measures

Primary Measures

  • Plasma Concentration of Rilpivirine (RPV)
    • Time Frame: Up to 72 weeks
    • Plasma samples will be analyzed to determine concentrations of RPV using a validated, specific, and sensitive method.

Secondary Measures

  • Number of Participants With Adverse Events (AEs)
    • Time Frame: Up to 72 weeks
    • An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
  • Number of Participants with Injection-Site Reactions
    • Time Frame: Up to 72 weeks
    • Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site.
  • Number of Participants with Abnormalities in 12-Lead Electrocardiograms (ECGs)
    • Time Frame: Up to 72 weeks
    • Number of participants with abnormalities in 12- lead ECGs (heart rate, PR, QRS and QT corrected [QTc]) will be reported.
  • Pain Assessment using Visual Analogue Scale (VAS)
    • Time Frame: Up to 72 weeks
    • Pain assessments will be performed by collecting pain intensity scores using 100-millimetre (mm) VAS.

Participating in This Clinical Trial

Inclusion Criteria

  • Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening (results must be available on Day -1) – Participant must be healthy on the basis of clinical laboratory tests performed at screening (results must be available prior to dosing on Day 1). If there are abnormalities, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator – All women participants must have a negative highly sensitive serum (Beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening and on Day -1 – A woman must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for at least 72 weeks after receiving the last dose of study intervention – A male participant (not vasectomized) who is heterosexually active with a woman of childbearing potential must agree to use two effective contraceptive methods for the duration of the study (72 weeks follow-up), or for at least 72 weeks after receiving the last dose of study intervention for those who do not complete the study Exclusion Criteria:

  • Participant with a history of or current illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study intervention to the participant or that could prevent, limit or confound the protocol specified assessments. This may include, but is not limited to, hepatic or renal dysfunction, cardiac disease, vascular, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, neurologic, hematologic, coagulation disorders (including any abnormal bleeding or blood dyscrasias), or psychiatric disturbances – Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence) – Participant has known allergies, hypersensitivity, or intolerance to any components of the formulation – Participants with the following ECG findings, if clinically significant: abnormal PR, QRS, and QTc intervals; rhythm abnormalities; evidence of acute ischemic changes – Participants with a history of clinically relevant skin disease such as, but not limited to, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Janssen Research & Development, LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Janssen Research & Development, LLC Clinical Trial, Study Director, Janssen Research & Development, LLC
  • Overall Contact(s)
    • Study Contact, 844-434-4210, JNJ.CT@sylogent.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.